Find valuable ACTEMRA® (tocilizumab) information, including an ACTEMRA® dosing calculator, RA patient brochure, ACTEMRA® prescription guide and the. Tocilizumab (Actemra) is a biologic reference guide with prescribing information, dosage, medication administration, and possible side effects. Each vial contains 80 mg of tocilizumab* in 4 ml (20 mg/ml). . Dose interruptions of tocilizumab for the following laboratory abnormalities are recommended in.
|Published (Last):||26 September 2018|
|PDF File Size:||17.29 Mb|
|ePub File Size:||8.57 Mb|
|Price:||Free* [*Free Regsitration Required]|
Two additional patients developed MAS during the long-term extension.
Resume mg at every other week and increase frequency to every week as clinically appropriate. Managing Infusion Reactions Acute infusion reaction can occur during the administration of tocilizumab or actemra prescribing information 24 hours of infusion.
ACTEMRA is indicated for the treatment of actemra prescribing information systemic juvenile idiopathic arthritis in patients 2 years of age and older. The information contained in this section of the site is intended for U. Shortness of breath or trouble breathing Swelling of lips, tongue, or face Chest pain Feeling dizzy or faint Moderate or severe abdominal pain or vomiting.
Forms & Documents | Genentech Rheumatology Access Solutions
Most commonly, these are generic drugs. Withdraw a volume of 0. Belimumab Benlysta Medication Guide: No information is available on presence of tocilizumab in human milk, the effects of drug on breastfed infant, or actemra prescribing information of drug on milk production.
Certolizumab Cimzia Medication Guide: The information contained in this section of the site is intended for U. Inforrmation Help Get more information. There was no clear relationship between decreases in neutrophils below 1 x 10 9 per L and the occurrence of serious infections.
Some people have died from these infections. In patients who develop an ANC less than per mm 3 treatment is not actemra prescribing information. The recommended adtemra of tocilizumab given once every 2 weeks as actemra prescribing information IV infusion is: Infection signs, with or without a fever, include sweating or chills; shortness of breath; warm, red or painful skin or sores on your body; feeling very actemra prescribing information muscle aches; blood in phlegm; diarrhea or stomach pain; cough; weight loss; burning when you urinate or urinating more often than normal Any actemra prescribing information the following conditions that may give you a higher chance of getting infections.
Call Genentech at Infection actekra, with or without a fever, include: The risks and benefits of treatment with ACTEMRA should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection.
People who experience severe or life-threatening CRS following chimeric antigen receptor T cell treatment age 2 years and above. Other Restrictions Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
We are here to help.
Anaphylaxis and other hypersensitivity reactions that required treatment discontinuation were reported in 0. In SC-II, the frequency of injection-site reactions was 7.
Contact immediately, as well as your healthcare provider or nurse, if you experience any of these reactions:. Has a current or recent infection or illness.
Print this section Print the entire contents of. The actemra prescribing information common serious infections included pneumonia, urinary tract infection, cellulitis, herpes zoster, gastroenteritis, diverticulitis, sepsis and bacterial arthritis. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Sweating or chills Shortness of breath Warm, red or painful skin or sores on prescribibg body Feel very tired Muscle aches Blood in phlegm Diarrhea or stomach pain Actemra prescribing information Weight loss Burning when you urinate or urinating more often than normal Any of the following conditions that may give you a higher chance of getting infections.
If the answer is yes to any of these questions, notify the ordering provider before initiating the infusion therapy. Most commonly, these are actemra prescribing information brand drugs.
Please select a treatment to continue
This information does not take the place actemra prescribing information talking actemra prescribing information your healthcare provider about your medical condition or your treatment. Contact the applicable plan provider for the most current information. These injection-site reactions were mild to moderate in severity. Has an upcoming surgery. Risks involved outweigh potential benefits. Platelets are blood cells that help with clotting, which stops bleeding increase in liver function test levels increase in blood cholesterol levels.
Physicians are encouraged to register patients and pregnant women actemra prescribing information encouraged to register themselves by calling Tocilizumab has not been studied in combination with biological DMARDs eg, TNF antagonists, IL-1R antagonists, anti-CD20 monoclonal antibodies, selective costimulation modulators and its use should be avoided in combination with these agents because of increased immunosuppression and risk of infection.
European Medicines Agency – System/website unavailable
Most commonly, these are “non-preferred” brand drugs or specialty prescription products. The majority resolved without any treatment and none necessitated drug discontinuation.
Gastrointestinal perforation — use with caution in patients who may be at increased risk. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. Undiluted vials and prefilled Actemra prescribing information syringes: These elevations did not result in apparent permanent or clinically evident hepatic injury in atemra trials.
Thanks for sharing this page. Subcutaneous Tocilizumab for subcutaneous administration is supplied as actemra prescribing information prefilled syringe which delivers 0. Do not dilute vials until after successfully obtaining intravenous access. The most common events observed were nasopharyngitis and upper respiratory tract infections.
Your email has been sent! Instruct the patient to remove from the refrigerator approximately minutes prior to injection.